Categorization of the status and outcome of preexisting and treatment-emergent AICs
| Status . | Outcome . |
|---|---|
| Preexisting AIC status at the start of treatment with targeted drug | |
| Resolved | Complete blood count normalization, no signs of hemolysis, and no transfusion support or other AIC-directed treatment (including steroids or thrombopoietin mimetics) |
| Controlled | Blood counts stable over time but not reaching the normal values, or presence of subclinical hemolysis (hemoglobin within normal limits but high reticulocyte count and/or low serum haptoglobin levels) |
| Active | Blood counts decreasing, requiring treatment change or additional medical treatment |
| Preexisting AIC outcome during treatment with targeted drug | |
| Resolved | Complete blood count normalization, no signs of hemolysis, and no transfusion support or other AIC-directed treatment (including steroids or thrombopoietin mimetics) |
| Improved | Blood count recovery without complete normalization, or presence of persistent signs of subclinical hemolysis (hemoglobin within normal limits but high reticulocyte count and/or low serum haptoglobin levels) |
| Stable | Absence of relevant changes in blood parameters |
| Worsened | Worsening of cytopenia or need of additional therapy to control AIC |
| Treatment-emergent AIC outcome during treatment with targeted drug | |
| Resolved | Complete blood count normalization, no signs of hemolysis, and no transfusion support or other AIC-directed treatment (including steroids or thrombopoietin mimetics) |
| Controlled | Blood counts stable over time but not reaching normal values, or presence of subclinical hemolysis (hemoglobin within normal limits but high reticulocyte count and/or low serum haptoglobin levels) |
| Active | Blood counts decreasing, requiring treatment change or additional medical treatment |
| Status . | Outcome . |
|---|---|
| Preexisting AIC status at the start of treatment with targeted drug | |
| Resolved | Complete blood count normalization, no signs of hemolysis, and no transfusion support or other AIC-directed treatment (including steroids or thrombopoietin mimetics) |
| Controlled | Blood counts stable over time but not reaching the normal values, or presence of subclinical hemolysis (hemoglobin within normal limits but high reticulocyte count and/or low serum haptoglobin levels) |
| Active | Blood counts decreasing, requiring treatment change or additional medical treatment |
| Preexisting AIC outcome during treatment with targeted drug | |
| Resolved | Complete blood count normalization, no signs of hemolysis, and no transfusion support or other AIC-directed treatment (including steroids or thrombopoietin mimetics) |
| Improved | Blood count recovery without complete normalization, or presence of persistent signs of subclinical hemolysis (hemoglobin within normal limits but high reticulocyte count and/or low serum haptoglobin levels) |
| Stable | Absence of relevant changes in blood parameters |
| Worsened | Worsening of cytopenia or need of additional therapy to control AIC |
| Treatment-emergent AIC outcome during treatment with targeted drug | |
| Resolved | Complete blood count normalization, no signs of hemolysis, and no transfusion support or other AIC-directed treatment (including steroids or thrombopoietin mimetics) |
| Controlled | Blood counts stable over time but not reaching normal values, or presence of subclinical hemolysis (hemoglobin within normal limits but high reticulocyte count and/or low serum haptoglobin levels) |
| Active | Blood counts decreasing, requiring treatment change or additional medical treatment |
AIC definitions are provided in supplemental Table 2.